Detecting Metastatic Bladder Cancer Using 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to retrospectively investigate the contribution of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) todetection of metastatic bladder cancer. Materials and MethodsThe present study included 79 patients (69 men and 10 women) undergoing 18F-FDGPET/CT upon suspicion of metastatic bladder cancer between July 2007 and April 2013. The mean age was 66.1 years with a standard deviation of 10.7 years (range, 21 to 85years). Patients were required to fast for 6 hours prior to scanning, and whole-body PETscanning from the skull base to the upper thighs was performed approximately 1 hour afterintravenous injection of 555 MBq of 18F-FDG. Whole body CT scanning was performed inthe cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuationcorrection. Suspicious recurrent or metastatic lesions were confirmed by histopathologyor clinical follow-up. ResultsThe sensitivity, specificity, positive predictive value, negative predictive value, and accuracyof 18F-FDG-PET/CT were 89%, 78%, 90%, 75%, and 86%, respectively. Conclusion18F-FDG-PET/CT can detect metastases with high sensitivity and positive predictive valuesin patients with metastatic bladder carcinoma.
Abstract
Purpose The purpose of this study was to retrospectively investigate the contribution of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) todetection of metastatic bladder cancer. Materials and MethodsThe present study included 79 patients (69 men and 10 women) undergoing 18F-FDGPET/CT upon suspicion of metastatic bladder cancer between July 2007 and April 2013. The mean age was 66.1 years with a standard deviation of 10.7 years (range, 21 to 85years). Patients were required to fast for 6 hours prior to scanning, and whole-body PETscanning from the skull base to the upper thighs was performed approximately 1 hour afterintravenous injection of 555 MBq of 18F-FDG. Whole body CT scanning was performed inthe cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuationcorrection. Suspicious recurrent or metastatic lesions were confirmed by histopathologyor clinical follow-up. ResultsThe sensitivity, specificity, positive predictive value, negative predictive value, and accuracyof 18F-FDG-PET/CT were 89%, 78%, 90%, 75%, and 86%, respectively. Conclusion18F-FDG-PET/CT can detect metastases with high sensitivity and positive predictive valuesin patients with metastatic bladder carcinoma.
참고문헌 (25)
- Ploeg M, "The present and future burden of urinary bladder cancer in the world", World J Urol, 27, pp.289~293 (2009)
- Siegel R, "Cancer statistics, 2011 : the impact of eliminating socioeconomic and racial disparities on premature cancer deaths", CA Cancer J Clin, 61, pp.212~236 (2011)
- Siegel R, "Cancer statistics, 2013", CA Cancer J Clin, 63, pp.11~30 (2013)
- Abdollah F, "Incidence, survival and mortality rates of stagespecific bladder cancer in United States : a trend analysis", Cancer Epidemiol, 37, pp.219~225 (2013)
- Kaufman DS, "Bladder cancer", Lancet, 374, pp.239~249 (2009)
- Stein JP, "Radical cystectomy in the treatment of invasive bladder cancer : long-term results in 1, 054 patients", J Clin Oncol, 19, pp.666~675 (2001)
- Sternberg CN, "Can patient selection for bladder preservation be based on response to chemotherapy?", Cancer, 97, pp.1644~1652 (2003)
- Barentsz JO, "MR imaging of the male pelvis", Eur Radiol, 9, pp.1722~1736 (1999)
- Bouchelouche K, "PET", CT and MRI in bladder cancer, 2012, pp.(S14), 7692~
- -Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma, "Int J Clin Oncol", 2008, 42~47
- Lu YY, "Clinical value of FDG PET or PET", CT in urinary bladder cancer : a systemic review and meta-analysis, 2012, pp.81, 2411~2416
- Harney JV, "Uptake of 2-deoxy, 2-(18F)fluoro-Dglucose in bladder cancer : animal localization and initial patient positron emission tomography", J Urol, 145, pp.279~283 (1991)
- Drieskens O, "FDG-PET for preoperative staging of bladder cancer", Eur J Nucl Med Mol Imaging, 32, pp.1412~1417 (2005)
- Apolo AB, "Clinical value of fluorine-18 2-fluoro-2-deoxy-Dglucose positron emission tomography", computed tomography in bladder cancer, 2010, pp.28, 3973~3978
- fluorodeoxyglucose positron emission tomography, "computed tomography for staging of muscle-invasive bladder carcinoma", J Clin Oncol, 27, pp.4314~4320 (2009)
- CT: a clinical guide, "PET and PET", pp.2009, Lin EC
- Anjos DA, "18F-FDG PET", CT delayed images after diuretic for restaging invasive bladder cancer, 2007, pp.48, 764~770
- Harkirat S, "Forced diuresis and dual-phase F-fluorodeoxyglucose-PET", CT scan for restaging of urinary bladder cancers, 2010, pp.20, 13~19
- Swinnen G, "FDG-PET", CT for the preoperative lymph node staging of invasive bladder cancer, 2010, pp.57, 641~647
- Lodde M, "Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma", BJU Int, 106, pp.658~663 (2010)
- Jensen TK, "Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography", computed axial tomography and magnetic resonance imaging : correlation with histopathology, 2011, pp.45, 122~128
- Liu IJ, "Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy", Urol Int, 77, pp.69~75 (2006)
- Mertens LS, "18F-fluorodeoxyglucose : positron emission tomography", computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer, 2014, pp.83, 393~398
- Golan S, "Comparison of 11Ccholine with 18F-FDG in positron emission tomography", computerized tomography for staging urothelial carcinoma : a prospective study, 2011, pp.186, 436~441
- El Fakhri G, "Improvement in lesion detection with whole-body oncologic time-of-flight PET", J Nucl Med, 52, pp.347~353 (2011)